FSL-1 TFA

• CAT Number: I045851
• Molecular Formula: C84H140N14O18S.xC2HF3O2
• Molecular Weight: 1666.16 (free acid)
• Purity: ≥95%

FSL-1 TFA, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection[1]. FSL-1 TFA induces MMP-9 production through TLR2 and NF-κB/AP-1 signaling pathways in monocytic THP-1 cells[2].
FSL-1 TFA significantly reduces HSV-2 replication in human vaginal epithelial cells (EC)[1].
FSL-1 TFA induces significant resistance to experimental genital HSV-2 infection through elaboration of a specific cytokine response profile[1].
FSL-1 TFA (50 ng/mL, 24 hours) induces MMP-9 expression at both mRNA and protein levels in human monocytic THP-1 cells[2].
FSL-1 TFA activates the MAP kinase/NF-κB signaling pathway[2].
FSL-1 TFA application significantly protectes against genital HSV-2 challenge in mice[1].

Reference

[1]. William A Rose 2nd, et al. FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection. Virol J. 2009 Nov 10;6:195.
 [Content Brief]

[2]. Cathryn J Kurkjian,et al. The Toll-Like Receptor 2/6 Agonist, FSL-1 Lipopeptide, Therapeutically Mitigates Acute Radiation Syndrome. Sci Rep. 2017 Dec 11;7(1):17355.
 [Content Brief]